Lupus News and Research

Latest Lupus News and Research

Researchers identify new genetic link to systemic scleroderma

An international research consortium including scientists from The University of Texas Health Science Center at Houston (UTHealth) has identified a new genetic link to the systemic form of scleroderma. Researchers believe a thorough understanding of the genetic nature of the disease is crucial to developing a cure.

30 Apr 2010

New data on Cimzia for Crohn’s Disease treatment to be demonstrated at DDW 2010

Studies and analyses of the Crohn’s Disease (CD) treatment Cimzia® (certolizumab pegol) demonstrating new data will be exhibited at Digestive Disease Week (DDW) 2010, taking place in New Orleans from May 1-5, 2010.

30 Apr 2010

Celgene's first-quarter non-GAAP total revenue up 31% to $789 million

Celgene Corporation announced non-GAAP net income of $294.6 million, or non-GAAP diluted earnings per share of $0.63 for the quarter ended March 31, 2010. Non-GAAP net income for the first quarter of 2009 was $205.1 million or non-GAAP diluted earnings per share of $0.44. Based on U.S. GAAP, Celgene reported net income of $234.4 million, or diluted earnings per share of $0.50 for the quarter ended March 31, 2010. GAAP net income for the first quarter of 2009 was $162.9 million, or diluted earnings per share of $0.35.

29 Apr 2010

Human Genome Sciences reports net loss of $47.9M for first-quarter 2010

Human Genome Sciences, Inc. today announced financial results for the quarter ended March 31, 2010, and provided highlights of recent key developments.

29 Apr 2010

LFA seeks grant applications from medical researchers to help advance understanding of lupus nephritis

The Lupus Foundation of America seeks grant applications from medical researchers to help advance the understanding of lupus nephritis, a serious and life-threatening complication of lupus that can affect as many as 40 percent of all people with lupus, and two-thirds of children with the disease.

24 Apr 2010

LFA felicitates Yale University professor on receipt of US DoD's PRMRP research grant

The Lupus Foundation of America, Inc. (LFA) congratulates Insoo Kang, M.D., Associate Professor of Medicine, Yale University for being selected to receive a $1.2 million research grant from the U.S. Department of Defense's (DoD) Congressionally Directed Peer Reviewed Medical Research Program (PRMRP). The DoD award will fund a three-year study that will investigate whether and why lupus patients make more of the chemical interleukin (IL-27), which causes decreased generation of T cells and is known to play an important role in autoimmunity and lupus.

24 Apr 2010

Actelion Pharmaceuticals launches Epoprostenol for Injection for treatment of primary pulmonary hypertension

Actelion Pharmaceuticals US, Inc. today announced the commercial availability of Epoprostenol for Injection, an improved formulation of epoprostenol that is stable at room temperature, for the treatment of primary pulmonary hypertension and pulmonary hypertension associated with scleroderma spectrum of disease in NYHA Class III and Class IV patients.

22 Apr 2010

People with vitiligo may have less risk of developing malignant melanoma: Research

People with the skin pigmentation disorder vitiligo may have less risk of developing life-threatening malignant melanoma, according to new research. The study also further confirms the suspicion that vitiligo is an autoimmune disease, which occur when the body's immune system reacts against its own tissues or organs.

22 Apr 2010

Plexxikon presents promising preclinical data from PLX3397 in vivo cancer studies

Plexxikon Inc. today announced promising preclinical data from in vivo cancer studies with PLX3397 demonstrating significant reduction in tumor burden, metastatic spread, bone erosion and cancer bone pain. PLX3397 is an oral, selective kinase inhibitor that down-modulates macrophages, microglia, osteoclasts and mast cells, all cell types targeted by this drug candidate. These cell types play a key role in cancer and metastasis.

21 Apr 2010

Positive results from pivotal Phase 3 trials of BENLYSTA in SLE patients

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced topline secondary endpoints from BLISS-76, the second of two pivotal Phase 3 trials of BENLYSTA™ (belimumab) in seropositive patients with systemic lupus erythematosus.

20 Apr 2010

TYSABRI drives Biogen Idec's first-quarter revenues of $1.1 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its first quarter 2010 results.

20 Apr 2010

Novartis withdraws EMA MAA for JOULFERON

Human Genome Sciences, Inc. today announced that Novartis has withdrawn a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for approval to market JOULFERON® (albinterferon alfa-2b, known in the United States as ZALBIN™) for the treatment of chronic hepatitis C.

19 Apr 2010

Results of study comparing REMICADE to azathioprine for Crohn's disease published

Findings published today in The New England Journal of Medicine from a first-of-its-kind comparator trial evaluating the anti-tumor necrosis factor (TNF)-alpha biologic treatment REMICADE (infliximab) in the treatment of moderately to severely active Crohn's disease in patients who were naive to immunomodulator and biologic therapy, showed that a significantly greater proportion of patients receiving REMICADE achieved steroid-free remission and mucosal healing compared with patients receiving azathioprine.

16 Apr 2010

Laquinimod may have neuroprotective properties in addition to anti-inflammatory effects for RRMS

Teva Pharmaceutical Industries Ltd. and Active Biotech today announced results from several studies demonstrating that laquinimod, a novel, investigational once-daily oral immunomodulator for relapsing remitting multiple sclerosis (RRMS) may have neuroprotective properties in addition to its anti-inflammatory effects.

16 Apr 2010

New studies supporting Teva Pharmaceutical Industries' CNS portfolio to be presented at AAN 2010

Teva Pharmaceutical Industries Ltd. today announced that several new studies supporting the company's innovative central nervous system portfolio will be presented at the 62nd American Academy of Neurology Annual Meeting in Toronto, April 10-17, 2010.

8 Apr 2010

Anthera Pharmaceuticals announces closing of underwriters' exercise of over-allotment option

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced the closing of the underwriters' exercise of their over-allotment option to purchase an additional 604,492 shares of Anthera's common stock, at a price of $7.00 per share.

7 Apr 2010

Dry-mouth and dry-eye symptoms often misdiagnosed by healthcare professionals

Results from a recent survey of 400 Sjogren's syndrome patients showed that half of those surveyed experienced common symptoms such as dry mouth or dry eyes for three or more years before receiving an accurate diagnosis from a healthcare professional.

6 Apr 2010

AnaptysBio, VLST collaborate to generate novel multi-antigen specific antibody therapeutics

AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company, today announced a collaboration with VLST Corporation to generate novel multi-antigen specific antibody therapeutics for the treatment of autoimmune and inflammatory disorders. This is the fourth collaboration announced by AnaptysBio during 2010.

5 Apr 2010

Feinstein Institute scientists seek sisters for lupus study

The SisSLE (Sisters of Women with Systemic Lupus Erythematosus) research study is looking for sisters: one with a diagnosis of systemic lupus erythematosus (SLE), an autoimmune disease and one (or more) who does not have lupus.

31 Mar 2010

WinRho SDF for ITP: Cangene announces new safety information

Cangene Corporation, in consultation with Health Canada, is informing Canadian patients and healthcare professionals of important new safety information concerning the use of WinRho SDF (Rho (D) Immune Globulin (Human)) for the treatment of immune thrombocytopenic purpura, also called immune thrombocytopenia, or ITP. WinRho SDF belongs to a group of biological medicines derived from human plasma known as immunoglobulins. It is administered in hospitals by infusion through the veins.

27 Mar 2010

Lupus News and Research

Latest Lupus News and Research

Researchers identify new genetic link to systemic scleroderma

New data on Cimzia for Crohn’s Disease treatment to be demonstrated at DDW 2010

Celgene's first-quarter non-GAAP total revenue up 31% to $789 million

Human Genome Sciences reports net loss of $47.9M for first-quarter 2010

LFA seeks grant applications from medical researchers to help advance understanding of lupus nephritis

LFA felicitates Yale University professor on receipt of US DoD's PRMRP research grant

Actelion Pharmaceuticals launches Epoprostenol for Injection for treatment of primary pulmonary hypertension

People with vitiligo may have less risk of developing malignant melanoma: Research

Plexxikon presents promising preclinical data from PLX3397 in vivo cancer studies

Positive results from pivotal Phase 3 trials of BENLYSTA in SLE patients

TYSABRI drives Biogen Idec's first-quarter revenues of $1.1 billion

Novartis withdraws EMA MAA for JOULFERON

Results of study comparing REMICADE to azathioprine for Crohn's disease published

Laquinimod may have neuroprotective properties in addition to anti-inflammatory effects for RRMS

New studies supporting Teva Pharmaceutical Industries' CNS portfolio to be presented at AAN 2010

Anthera Pharmaceuticals announces closing of underwriters' exercise of over-allotment option

Dry-mouth and dry-eye symptoms often misdiagnosed by healthcare professionals

AnaptysBio, VLST collaborate to generate novel multi-antigen specific antibody therapeutics

Feinstein Institute scientists seek sisters for lupus study

WinRho SDF for ITP: Cangene announces new safety information

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Lupus News and Research

Latest Lupus News and Research

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Newsletters you may be interested in